These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 22158616)

  • 1. Identification of functionally distinct TRAF proinflammatory and phosphatidylinositol 3-kinase/mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (PI3K/MEK) transforming activities emanating from RET/PTC fusion oncoprotein.
    Wixted JH; Rothstein JL; Eisenlohr LC
    J Biol Chem; 2012 Feb; 287(6):3691-703. PubMed ID: 22158616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway.
    Lodyga M; De Falco V; Bai XH; Kapus A; Melillo RM; Santoro M; Liu M
    Oncogene; 2009 Feb; 28(7):937-49. PubMed ID: 19060924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
    Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
    Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
    Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unique signaling properties of CTAR1 in LMP1-mediated transformation.
    Mainou BA; Everly DN; Raab-Traub N
    J Virol; 2007 Sep; 81(18):9680-92. PubMed ID: 17626074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.
    Henderson YC; Chen Y; Frederick MJ; Lai SY; Clayman GL
    Mol Cancer Ther; 2010 Jul; 9(7):1968-76. PubMed ID: 20587665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
    Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
    J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase.
    Knauf JA; Kuroda H; Basu S; Fagin JA
    Oncogene; 2003 Jul; 22(28):4406-12. PubMed ID: 12853977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
    Xing M
    Thyroid; 2010 Jul; 20(7):697-706. PubMed ID: 20578891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
    Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
    Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation.
    Hwang JH; Kim DW; Suh JM; Kim H; Song JH; Hwang ES; Park KC; Chung HK; Kim JM; Lee TH; Yu DY; Shong M
    Mol Endocrinol; 2003 Jun; 17(6):1155-66. PubMed ID: 12637586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Three Novel Fusion Oncogenes, SQSTM1/NTRK3, AFAP1L2/RET, and PPFIBP2/RET, in Thyroid Cancers of Young Patients in Fukushima.
    Iyama K; Matsuse M; Mitsutake N; Rogounovitch T; Saenko V; Suzuki K; Ashizawa M; Ookouchi C; Suzuki S; Mizunuma H; Fukushima T; Suzuki S; Yamashita S
    Thyroid; 2017 Jun; 27(6):811-818. PubMed ID: 28351223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer.
    Sáez JM
    Anticancer Agents Med Chem; 2013 Mar; 13(3):483-95. PubMed ID: 22583421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAF-1 promotes survival of thyroid cancer cells harboring RET/PTC1 rearrangement independently of ERK activation.
    Castro L; Alves S; Chaves SR; Costa JL; Soares P; Preto A
    Mol Cell Endocrinol; 2015 Nov; 415():64-75. PubMed ID: 26265449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
    Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
    Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic alterations in papillary thyroid cancers of young patients.
    Sassolas G; Hafdi-Nejjari Z; Ferraro A; Decaussin-Petrucci M; Rousset B; Borson-Chazot F; Borbone E; Berger N; Fusco A
    Thyroid; 2012 Jan; 22(1):17-26. PubMed ID: 22150560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
    Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells.
    Miyagi E; Braga-Basaria M; Hardy E; Vasko V; Burman KD; Jhiang S; Saji M; Ringel MD
    Mol Carcinog; 2004 Oct; 41(2):98-107. PubMed ID: 15378648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src.
    Jin W; Yun C; Hobbie A; Martin MJ; Sorensen PH; Kim SJ
    Cancer Res; 2007 Apr; 67(7):3192-200. PubMed ID: 17409427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.